Small Cap Feast
Small Cap Feast – 18th January 2017
Dish of the Day:
No AIM Joiners Today
No AIM Joiners Today
Off the Menu:
No AIM Leavers Today
No AIM Leavers Today
What’s Cooking in the IPO Kitchen?
Global Energy Development (GED.L) — To be renamed Nautilus Marine Services. Schedule 1 from developer and seller of hydrocarbons and related products. Reverse takeover. Raising $10.5m via a convertible. Expected 9 Feb.
Eco (Atlantic) Oil & Gas—TSX-V listed oil and gas exploration has announced its intention to float on AIM. Assets in Guyana and Namibia. Proposed £2m-£3m fundraise.
Diversified Gas & Oil—According to LSE website first day of trading on AIM now expected for 30 January.
Fitbug Holdings* (FITB.L) 0.17p £2.03m
The digital wellness technology provider for corporate organisations, announced a customer win with a global financial services group in Asia. The customer will use Fitbug’s digital wellness services to help maximise employee performance, with the end goals of improving employee engagement, and reducing absenteeism and risk of chronic illness.
Fitbug has secured an initial 1-year corporate wellness programme, which includes ongoing service revenue, together with an order for 14,000 devices. The devices were shipped in December and the programme is rolling out early this year. The client wishes to remain anonymous at this time.
Christie Group (CTG.L) 89p £23.47m
The provider of Professional Business Services and Stock & Inventory Systems & Services to the leisure, retail and care markets, announced that Christie & Co, its specialist provider of agency and advisory services, has successfully brokered the sale of Magic Nurseries to Les Petits Chaperons Rouges, France’s leading private nursery chain. “When the time came for us to consider the sale of our business, Courteney Donaldson at Christie & Co was our first and only port of call.” No financial details were provided.
Tribal Group (TRB.L) 64.75p £126.5m
FY Dec 16 trading update from the provider of products, services and software to the international higher education, further education, training and vocational learning markets. Following a good second half, the Board anticipates that Group revenues will be in line with its expectations for the year to 31 December 2016 and the performance of the Group will be materially ahead. Annualised cost savings of £8.5m have been delivered by the year end and further efficiency savings are expected in 2017. The Group’s balance sheet remains strong following the fund raising and sale of the Synergy business early in the year. The Group ended the year with £8.8m of cash, up from the £5.7 at the end of the half year. FY16E revenue £88.7m and £2.28m PBT.
Plant Health Care (PHC.L) 15.5p £22.9m
FYDec16 trading and research update from the provider of novel patent-protected biological products to the global agriculture markets. Revenue of approximately $6.3 million; sales in the United States decreased by approximately $1.1 million, due to the decision to reduce in-market inventories. Growth outside the United States was 15% in constant currency. Cash and equivalents $10.1m. New distribution agreements signed in H2 show potential for growth in Commercial sales during 2017. Innatus™ 3G trials continued to show good results.
Two new PREtec peptide platforms: T-Rex 3G and Y-Max 3G have been presented to industry players with initial agreements signed.
Deltex Medical (DEMG.L) 4p £11.4m
FYDec16 trading update from the specialist in oesophageal Doppler monitoring. Group revenues for 2016 expected to be £6.3m (2015: £6.2m: £6.4m including research barter sales). US+40%. Run-rate going into 2017 c 50% higher than at same stage in 2016 with continuing growth anticipated in 2017, both from existing and new accounts (two platform accounts announced separately today). International up 20%. UK down 26% but positive market reception to new probes and new clinical evidence leading to improving trend in probe consumption in H2. Cash of £0.6m. £30k monthly cost savings in 2017 from in-house production. Substantially reduced cash burn in H2 2016 reflecting full effect of approximately £1m of annualised cost savings and growth in high margin US probe sales.
Mercia Technologies (MERC.L) 50.2p £106.8m
The investment group focused on the creation, funding and scaling of innovative technology businesses with high growth potential from the UK regions, announced a new direct investment of up to £1.9 million in Faradion Limited, a company focused on the development and commercialisation of advanced, low-cost battery materials. Mercia’s investment is part of a syndicated investment round of up to £3.2 million .The current investment round will be used to commercialise Faradion’s lead product, a novel, low-cost sodium-ion battery technology from which Mercia believes significant value will be derived over time.
Draper Esprit (GROW.L) 347p £141.4m
The venture capital firm involved in the creation, funding and development of high-growth digital technology businesses, has doubled its equity stake in TrustPilot, investing a further $6.9 million (£5.5 million). Draper Esprit first invested in Trustpilot in 2013, with a follow on investment in 2015 and including this current investment, has now invested £11 million. Founded in 2007, Trustpilot is a global, multi-language review community. Trustpilot has customers in 65 countries.
Midwich (MIDW.L) 224.75p £178.56m
FYDec16 trading update from the specialist audio visual and document solutions distributor to the trade market. The Group’s trading momentum continued in H2 and it also benefited from the continued weakness in Sterling. Growth was seen across all of the Group’s divisions, in particular its overseas businesses, and it has seen a better than expected contribution from its most recent UK acquisition, Holdan. Now expects to report revenue of approximately £370m, +c.18%. FX accounts for c.3% of this growth. Gross margin improvement in line with the Board’s expectations. The Board now anticipates reporting adjusted profit before tax for 2016 comfortably ahead of its previous expectations. FY16E PE 14.1 x.
NAHL Group (NAHL.L) 135.5p £61.45m
In-line FYDec16 trading update from marketing and services business focused on the UK consumer legal market. Ministry of Justice response to consultation regarding Personal Injury claims now due to be published in April. “Fitzalan and Bush, the Group’s Conveyancing and Critical Care divisions, are unaffected by this consultation and we expect both to continue to make good progress in 2017.” The Group intends to propose a final dividend, payable in May 2017. FY16E £50.3m and EPS of 29.6p. Div 19.15p. 14.2% yield!
Hydrogen Group (HYDG.L) 36.5p £8.74m
FYDec16 trading update from global specialist recruitment business. The Board expects to report net fee income for the year of c.£17.8m and a return to profitability generating a PBT of c.£0.75m as a result of the Group’s strategy and a renewed focus on building market leading niches within the Group. The Group’s balance sheet remains strong with net cash expected to be £2.0m (2015: £2.6m) with the reduction in cash primarily due to an increase in trade debtors. The business has a strong contractor base, a diversified client base internationally and is well positioned to take advantage of opportunities in 2017.
Emily Liu, CFA, CAIA
0203 764 2344
0203 764 2345
*A corporate client of Hybridan LLP
This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.
The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).
Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.
This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.
Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.
Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
If you would like to unsubscribe, please email email@example.com with “unsubscribe me”.